{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:45:17Z","timestamp":1767624317708,"version":"3.40.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04316-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T20:27:26Z","timestamp":1734640046000},"page":"1835-1850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients"],"prefix":"10.1007","volume":"57","author":[{"given":"Ahmed A.","family":"Abo Elnaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Serag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Alsaied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basma Badrawy","family":"Khalefa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaisingh","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouk","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman M.","family":"Elettreby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"4316_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.644363","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Shi Z, Ouyang N, Ruan X (2021) Hyperphosphatemia and cardiovascular disease. Front Cell Dev Biol 9:644363. https:\/\/doi.org\/10.3389\/fcell.2021.644363","journal-title":"Front Cell Dev Biol"},{"key":"4316_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","volume":"24","author":"AM Shaman","year":"2016","unstructured":"Shaman AM, Kowalski SR (2016) Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J 24:494\u2013505. https:\/\/doi.org\/10.1016\/j.jsps.2015.01.009","journal-title":"Saudi Pharm J"},{"key":"4316_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/biomedicines9040404","volume":"9","author":"P Dube","year":"2021","unstructured":"Dube P, DeRiso A, Patel M et al (2021) Vascular calcification in chronic kidney disease: diversity in the vessel wall. Biomedicines 9:404. https:\/\/doi.org\/10.3390\/biomedicines9040404","journal-title":"Biomedicines"},{"key":"4316_CR4","volume-title":"StatPearls","author":"R Goyal","year":"2024","unstructured":"Goyal R, Jialal I (2024) Hyperphosphatemia. StatPearls. StatPearls Publishing, Treasure Island"},{"key":"4316_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4103\/2230-8210.183457","volume":"20","author":"S Vikrant","year":"2016","unstructured":"Vikrant S, Parashar A (2016) Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: a study from a tertiary care hospital in India. Indian J Endocrinol Metab 20:460\u2013467. https:\/\/doi.org\/10.4103\/2230-8210.183457","journal-title":"Indian J Endocrinol Metab"},{"key":"4316_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.22159\/ijpps.2017v9i12.22425","volume":"9","author":"SA Rabbani","year":"2017","unstructured":"Rabbani SA, Sathvik SB, Rao PG et al (2017) hyperphosphatemia in end stage renal disease: prevalence and patients characteristics of multiethnic population of United Arab Emirates. Int J Pharm Pharm Sci 9:283. https:\/\/doi.org\/10.22159\/ijpps.2017v9i12.22425","journal-title":"Int J Pharm Pharm Sci"},{"key":"4316_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.34067\/KID.0000000000000262","volume":"4","author":"K Kalantar-Zadeh","year":"2023","unstructured":"Kalantar-Zadeh K, Forfang D, Bakris G et al (2023) Managing phosphate burden in patients receiving dialysis: beyond phosphate binders and diet. Kidney360 4:1650\u20131656. https:\/\/doi.org\/10.34067\/KID.0000000000000262","journal-title":"Kidney360"},{"key":"4316_CR8","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1080\/14656566.2023.2243817","volume":"24","author":"V Cernaro","year":"2023","unstructured":"Cernaro V, Longhitano E, Calabrese V et al (2023) Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opin Pharmacother 24:1737\u20131746. https:\/\/doi.org\/10.1080\/14656566.2023.2243817","journal-title":"Expert Opin Pharmacother"},{"key":"4316_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IJNRD.S385826","volume":"17","author":"V Cernaro","year":"2024","unstructured":"Cernaro V, Longhitano E, Casuscelli C et al (2024) Hyperphosphatemia in chronic kidney disease: the search for new treatment paradigms and the role of tenapanor. Int J Nephrol Renovasc Dis 17:151\u2013161. https:\/\/doi.org\/10.2147\/IJNRD.S385826","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"4316_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1310\/hpj5104-312","volume":"51","author":"R Robison","year":"2016","unstructured":"Robison R, Cooney D, Low MB, Desai N (2016) Sevelamer carbonate and lanthanum usage evaluation and cost considerations at a veteran\u2019s affairs medical center. Hosp Pharm 51:312\u2013319. https:\/\/doi.org\/10.1310\/hpj5104-312","journal-title":"Hosp Pharm"},{"key":"4316_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4103\/0253-7613.56074","volume":"41","author":"PT Scaria","year":"2009","unstructured":"Scaria PT, Gangadhar R, Pisharody R (2009) Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. Indian J Pharmacol 41:187\u2013191. https:\/\/doi.org\/10.4103\/0253-7613.56074","journal-title":"Indian J Pharmacol"},{"key":"4316_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"K-U Eckardt","year":"2009","unstructured":"Eckardt K-U, Kasiske BL (2009) Foreword. Kidney Int 76:S1\u2013S2. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int"},{"key":"4316_CR13","doi-asserted-by":"publisher","first-page":"c259","DOI":"10.1159\/000313484","volume":"115","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Li M, Lu Y et al (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115:c259\u2013c267. https:\/\/doi.org\/10.1159\/000313484","journal-title":"Nephron Clin Pract"},{"key":"4316_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5414\/CNP65191","volume":"65","author":"WF Finn","year":"2006","unstructured":"Finn WF (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. CN 65:191\u2013202. https:\/\/doi.org\/10.5414\/CNP65191","journal-title":"CN"},{"key":"4316_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007790","author":"AG Spencer","year":"2014","unstructured":"Spencer AG, Labonte ED, Rosenbaum DP et al (2014) Intestinal inhibition of the Na+ \/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3007790","journal-title":"Sci Transl Med"},{"key":"4316_CR16","doi-asserted-by":"publisher","first-page":"eaam6474","DOI":"10.1126\/scitranslmed.aam6474","volume":"10","author":"AJ King","year":"2018","unstructured":"King AJ, Siegel M, He Y et al (2018) Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10:eaam6474. https:\/\/doi.org\/10.1126\/scitranslmed.aam6474","journal-title":"Sci Transl Med"},{"key":"4316_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18433\/jpps32284","volume":"25","author":"T Lin","year":"2022","unstructured":"Lin T, Al-Makki A, Shepler B (2022) Tenapanor: a new treatment option for hyperphosphatemia in end stage kidney disease. J Pharm Pharm Sci 25:77\u201383. https:\/\/doi.org\/10.18433\/jpps32284","journal-title":"J Pharm Pharm Sci"},{"key":"4316_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1744-9987.14028","volume":"27","author":"H Luo","year":"2023","unstructured":"Luo H, Feng J, Zhang Y et al (2023) Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Apher Dial 27:839\u2013847. https:\/\/doi.org\/10.1111\/1744-9987.14028","journal-title":"Ther Apher Dial"},{"key":"4316_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4316_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions 1st ed","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions 1st ed. Wiley"},{"key":"4316_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4316_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"unstructured":"StataCorp (2023) Stata statistical software","key":"4316_CR23"},{"unstructured":"RevMan. https:\/\/training.cochrane.org\/online-learning\/core-software\/revman. Accessed 14 Sep 2023","key":"4316_CR24"},{"unstructured":"PlotDigitizer. In: PlotDigitizer. https:\/\/plotdigitizer.com. Accessed 28 Apr 2024","key":"4316_CR25"},{"unstructured":"Cochrane handbook for systematic reviews of interventions. https:\/\/training.cochrane.org\/handbook. Accessed 5 Jul 2024","key":"4316_CR26"},{"key":"4316_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"4316_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4316_CR29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M (2001) Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 54:1046\u20131055. https:\/\/doi.org\/10.1016\/S0895-4356(01)00377-8","journal-title":"J Clin Epidemiol"},{"key":"4316_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2215\/CJN.09050815","volume":"11","author":"GA Block","year":"2016","unstructured":"Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al (2016) Effect of tenapanor on interdialytic weight gain in patients on hemodialysis. CJASN 11:1597\u20131605. https:\/\/doi.org\/10.2215\/CJN.09050815","journal-title":"CJASN"},{"key":"4316_CR31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1681\/ASN.2016080855","volume":"28","author":"GA Block","year":"2017","unstructured":"Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al (2017) Effect of tenapanor on serum phosphate in patients receiving hemodialysis. JASN 28:1933\u20131942. https:\/\/doi.org\/10.1681\/ASN.2016080855","journal-title":"JASN"},{"key":"4316_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1681\/ASN.2018080832","volume":"30","author":"GA Block","year":"2019","unstructured":"Block GA, Rosenbaum DP, Yan A, Chertow GM (2019) Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. JASN 30:641\u2013652. https:\/\/doi.org\/10.1681\/ASN.2018080832","journal-title":"JASN"},{"key":"4316_CR33","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.34067\/KID.0002002021","volume":"2","author":"GA Block","year":"2021","unstructured":"Block GA, Bleyer AJ, Silva AL et al (2021) Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM). Kidney360 2:1600\u20131610. https:\/\/doi.org\/10.34067\/KID.0002002021","journal-title":"Kidney360"},{"key":"4316_CR34","doi-asserted-by":"publisher","first-page":"sfad216","DOI":"10.1093\/ckj\/sfad216","volume":"17","author":"L Gan","year":"2024","unstructured":"Gan L, Xing L, Xu Y et al (2024) Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial. Clin Kidney J 17:sfad216. https:\/\/doi.org\/10.1093\/ckj\/sfad216","journal-title":"Clin Kidney J"},{"key":"4316_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ekir.2021.11.008","volume":"7","author":"M Inaba","year":"2022","unstructured":"Inaba M, Une Y, Ikejiri K et al (2022) Dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in Japan\u2014a phase 2 randomized trial. Kidney Int Rep 7:177\u2013188. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.008","journal-title":"Kidney Int Rep"},{"key":"4316_CR36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ekir.2023.08.003","volume":"8","author":"K Nitta","year":"2023","unstructured":"Nitta K, Itoyama S, Ikejiri K et al (2023) Randomized study of tenapanor added to phosphate binders for patients with refractory hyperphosphatemia. Kidney Int Rep 8:2243\u20132253. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.003","journal-title":"Kidney Int Rep"},{"key":"4316_CR37","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1681\/ASN.2020101398","volume":"32","author":"PE Pergola","year":"2021","unstructured":"Pergola PE, Rosenbaum DP, Yang Y, Chertow GM (2021) A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). JASN 32:1465\u20131473. https:\/\/doi.org\/10.1681\/ASN.2020101398","journal-title":"JASN"},{"key":"4316_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1159\/000516156","volume":"52","author":"T Shigematsu","year":"2021","unstructured":"Shigematsu T, Une Y, Ikejiri K et al (2021) Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia. Am J Nephrol 52:496\u2013506. https:\/\/doi.org\/10.1159\/000516156","journal-title":"Am J Nephrol"},{"key":"4316_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10157-023-02406-1","volume":"28","author":"M Nakayama","year":"2024","unstructured":"Nakayama M, Kobayashi S, Kusakabe M et al (2024) Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial. Clin Exp Nephrol 28:153\u2013164. https:\/\/doi.org\/10.1007\/s10157-023-02406-1","journal-title":"Clin Exp Nephrol"},{"key":"4316_CR40","doi-asserted-by":"publisher","first-page":"19100","DOI":"10.1038\/s41598-023-45080-9","volume":"13","author":"F Koiwa","year":"2023","unstructured":"Koiwa F, Sato Y, Ohara M et al (2023) Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia. Sci Rep 13:19100. https:\/\/doi.org\/10.1038\/s41598-023-45080-9","journal-title":"Sci Rep"},{"key":"4316_CR41","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.ekir.2021.06.030","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Sato Y, Ikejiri K et al (2021) Effect of tenapanor on phosphate binder pill burden in hemodialysis patients. Kidney Int Rep 6:2371\u20132380. https:\/\/doi.org\/10.1016\/j.ekir.2021.06.030","journal-title":"Kidney Int Rep"},{"key":"4316_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ki.2008.130","volume":"74","author":"KA Hruska","year":"2008","unstructured":"Hruska KA, Mathew S, Lund R et al (2008) Hyperphosphatemia of chronic kidney disease. Kidney Int 74:148\u2013157. https:\/\/doi.org\/10.1038\/ki.2008.130","journal-title":"Kidney Int"},{"key":"4316_CR43","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"key":"4316_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"G Block","year":"1998","unstructured":"Block G, Hulbert-Shearon T, Levin N, Port F (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607\u2013617. https:\/\/doi.org\/10.1053\/ajkd.1998.v31.pm9531176","journal-title":"Am J Kidney Dis"},{"key":"4316_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00041552-200109000-00003","volume":"10","author":"NW Levin","year":"2001","unstructured":"Levin NW, Hoenich NA (2001) Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 10:563\u2013568. https:\/\/doi.org\/10.1097\/00041552-200109000-00003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4316_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","volume":"32","author":"Y Isaka","year":"2021","unstructured":"Isaka Y, Hamano T, Fujii H et al (2021) Optimal phosphate control related to coronary artery calcification in dialysis patients. JASN 32:723\u2013735. https:\/\/doi.org\/10.1681\/ASN.2020050598","journal-title":"JASN"},{"unstructured":"Renagel (sevelamer hydrochloride) tablet for oral use. Prescribing in-formation (revised 2016)","key":"4316_CR47"},{"unstructured":"Fosrenol (lanthanum carbonate) chewable tablets\/oral powder for oral use. Prescribing information (revised 2016)","key":"4316_CR48"},{"unstructured":"Auryxia (ferric citrate) for oral use. Prescribing information (revised 2015)","key":"4316_CR49"},{"key":"4316_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10157-016-1302-8","volume":"21","author":"S Johansson","year":"2017","unstructured":"Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M (2017) A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol 21:407\u2013416. https:\/\/doi.org\/10.1007\/s10157-016-1302-8","journal-title":"Clin Exp Nephrol"},{"key":"4316_CR51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-017-0614-0","volume":"38","author":"DP Rosenbaum","year":"2018","unstructured":"Rosenbaum DP, Yan A, Jacobs JW (2018) Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig 38:341\u2013351. https:\/\/doi.org\/10.1007\/s40261-017-0614-0","journal-title":"Clin Drug Investig"},{"key":"4316_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"4316_CR53","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/j.1572-0241.2007.01321.x","volume":"102","author":"AE Cano","year":"2007","unstructured":"Cano AE, Neil AK, Kang J-Y et al (2007) Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol 102:1990\u20131997. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01321.x","journal-title":"Am J Gastroenterol"},{"key":"4316_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41100-019-0246-3","volume":"5","author":"R Ikee","year":"2019","unstructured":"Ikee R, Yano K, Tsuru T (2019) Constipation in chronic kidney disease: it is time to reconsider. Ren Replace Ther 5:51. https:\/\/doi.org\/10.1186\/s41100-019-0246-3","journal-title":"Ren Replace Ther"},{"key":"4316_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00424-018-2231-z","volume":"471","author":"G Jacquillet","year":"2019","unstructured":"Jacquillet G, Unwin RJ (2019) Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi). Pflug Arch Eur J Physiol 471:83\u201398. https:\/\/doi.org\/10.1007\/s00424-018-2231-z","journal-title":"Pflug Arch Eur J Physiol"},{"key":"4316_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ndt\/gfy061","volume":"34","author":"GA Block","year":"2019","unstructured":"Block GA, Rosenbaum DP, Yan A et al (2019) The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol Dial Transpl 34:339\u2013346. https:\/\/doi.org\/10.1093\/ndt\/gfy061","journal-title":"Nephrol Dial Transpl"},{"key":"4316_CR57","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1172\/JCI36479","volume":"118","author":"LD Quarles","year":"2008","unstructured":"Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820\u20133828. https:\/\/doi.org\/10.1172\/JCI36479","journal-title":"J Clin Invest"},{"key":"4316_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","volume":"60","author":"JH Ix","year":"2012","unstructured":"Ix JH, Katz R, Kestenbaum BR et al (2012) Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals. J Am Coll Cardiol 60:200\u2013207. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.040","journal-title":"J Am Coll Cardiol"},{"key":"4316_CR59","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1067\/msy.2002.128692","volume":"132","author":"EG Almqvist","year":"2002","unstructured":"Almqvist EG, Bondeson A-G, Bondeson L et al (2002) Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 132:1126\u20131132. https:\/\/doi.org\/10.1067\/msy.2002.128692","journal-title":"Surgery"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04316-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04316-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04316-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:12:55Z","timestamp":1746281575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04316-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4316"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04316-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}